4.6 Review

Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature

Journal

JOURNAL OF INFECTION AND PUBLIC HEALTH
Volume 15, Issue 11, Pages 1225-1233

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.jiph.2022.09.011

Keywords

Selenium; COVID-19; SARS-CoV-2; Clinical trials; Patent

Ask authors/readers for more resources

Selenium plays an important role in preventing/treating COVID-19 by reducing oxidative stress, inhibiting viral enzymes, and regulating inflammatory response. Clinical studies and patent literature suggest that selenium monotherapy or combination with other nutritional supplements/drugs could be practical for COVID-19 prevention/treatment. Selenium deficiency is correlated with COVID-19, indicating promising treatment outcomes with selenium supplementation. Thus, there is a significant need to develop novel selenium-based compositions and dosage forms to combat COVID-19 effectively.
Selenium is an indispensable trace element for all living organisms. It is an essential structural component of several selenium-dependent enzymes, which support the human body's defense mechanism. Recently, the significance of selenium in preventing/treating COVID-19 has been documented in the literature. This review highlights the clinical studies, compositions, and patent literature on selenium to prevent/treat COVID-19. Selenium exerts its anti-COVID-19 action by reducing oxidative stress, declining the expression of the ACE-2 receptor, lowering the discharge of pro-inflammatory substances, and inhibiting the 3CLPro (main protease) and PLpro enzyme of SARS-CoV-2. The data of clinical studies, inventive compositions, and patent literature revealed that selenium monotherapy and its compositions with other nutritional supplements/ drugs (vitamin, iron, zinc, copper, ferulic acid, resveratrol, spirulina, N-acetylcysteine, fish oil, many herbs, doxycycline, azithromycin, curcumin, quercetin, etc.,) might be practical to prevent/treat COVID-19. The studies have also suggested a correlation between COVID-19 and selenium deficiency. This indicates that adequate selenium supplementation may provide promising treatment outcomes in COVID-19 patients. The authors foresee the development and commercialization of Selenium-based compositions and dosage forms (spray, inhalers, control release dosage forms, etc.) to battle COVID-19. We also trust that numerous sele-nium-based compositions are yet to be explored. Accordingly, there is good scope for scientists to work on developing novel and inventive selenium-based compositions to fight against COVID-19. However, there is also a need to consider the narrow therapeutic window and chemical interaction of selenium before de-veloping selenium-based compositions.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/li-censes/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available